Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 7/20 | 0.47 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.42 |
| ▸ | HPGDS | O60760 | 2/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | KIF20B | Q96Q89 | 1/20 | 0.40 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5758675 | 0.87 | SCN2A (0.54) | NPY5RSCN2AHPGDSTRPV1SSTR3 | |
| SCHEMBL5758452 | 0.83 | HPGDS (0.57) | NPY5RSCN2AHPGDSABL1 | |
| SCHEMBL5756074 | 0.82 | SCN2A (0.49) | NPY5RSCN2AHPGDSTRPV1SSTR3 | |
| SCHEMBL5758399 | 0.81 | SCN2A (0.47) | NPY5RSCN2AHPGDSTRPV1SSTR3 | |
| SCHEMBL5758137 | 0.81 | SCN2A (0.62) | NPY5RSCN2AHPGDSTRPV1SSTR3 | |
| SCHEMBL5758378 | 0.79 | CNR1 (0.41) | HPGDS | |
| SCHEMBL5755506 | 0.78 | PDE10A (0.41) | NPY5RHPGDSSSTR3 | |
| SCHEMBL5756845 | 0.77 | SCN2A (0.44) | NPY5RSCN2ATRPV1 | |
| SCHEMBL5756970 | 0.76 | SSTR3 (0.42) | NPY5RHPGDSSSTR3 | |
| SCHEMBL5759555 | 0.75 | HPGDS (0.53) | NPY5RSCN2AHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1194144-B1 | ANTIBACTERIAL COMPOUNDS | AFFINIUM PHARM INC (CA) | 2006-11-02 | — | — | EP | claimed |
| US-20030149089-A1 | Antibacterial compounds | SMITHKLINE BEECHAM CORPORATION | 2003-08-07 | — | — | US | claimed |
| EP-1194144-B1 | ANTIBACTERIAL COMPOUNDS | AFFINIUM PHARM INC (CA) | 2006-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149089-A1 | Antibacterial compounds | MRPL21, MRPS28, SPOUT1 | NPY5R 4061/4885SCN2A 1133/4885HPGDS 2610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.